Literature DB >> 21283994

Re-evaluating the impact of tumor size on survival following pancreaticoduodenectomy for pancreatic adenocarcinoma.

Mechteld C de Jong1, Fuyu Li, John L Cameron, Christopher L Wolfgang, Barish H Edil, Joseph M Herman, Michael A Choti, Frederick Eckhauser, Kenzo Hirose, Richard D Schulick, Timothy M Pawlik.   

Abstract

BACKGROUND AND OBJECTIVES: Following resection of pancreatic adenocarcinoma, tumor size has been considered a key prognostic feature; however, this remains controversial. We sought to examine the association of size with outcomes following resection of pancreatic adenocarcinoma.
METHODS: Between 1970 and 2010, 1,697 patients with pancreatic adenocarcinoma at the Johns Hopkins Hospital underwent curative intent pancreaticoduodenectomy. Prognostic factors were identified by univariate and multivariate analyses.
RESULTS: Of 1,697 patients, tumor size was ≤ 2 cm in 418 (24.6%) patients, 2-5 cm in 1,070 (63.1%) patients, and ≥ 5 cm in 209 (12.3%) patients. On univariate analyses, 5-year survival was inversely proportional to tumor size (≤ 2 cm: 28.8% vs. 2-5 cm: 19.4% vs. ≥ 5 cm: 14.2%; P < 0.001). Size correlated with the risk of other adverse factors, with larger tumors being more likely to be associated with nodal disease and poor differentiation (both P < 0.05). On multivariate analysis, the 2 cm cut-off was not associated with survival, while nodal disease (HR = 1.59; P = 0.006) and poor differentiation (HR = 1.59; P = 0.04) remained predictive of outcome, regardless of size.
CONCLUSION: The cut-off value of 2 cm is not independently associated with outcome, however, tumor size was strongly associated with the risk of other adverse prognostic factors. The effect of size on prognosis was largely attributable to these other biologic factors rather than tumor size itself.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21283994      PMCID: PMC3578317          DOI: 10.1002/jso.21883

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  36 in total

1.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

2.  Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer.

Authors:  J L Cameron; D W Crist; J V Sitzmann; R H Hruban; J K Boitnott; A J Seidler; J Coleman
Journal:  Am J Surg       Date:  1991-01       Impact factor: 2.565

3.  Risk factors for cancer in hereditary pancreatitis. International Hereditary Pancreatitis Study Group.

Authors:  A B Lowenfels; P Maisonneuve; D C Whitcomb
Journal:  Med Clin North Am       Date:  2000-05       Impact factor: 5.456

Review 4.  Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium.

Authors:  Robert C Miller; Matthew J Iott; Michele M Corsini
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-10-01       Impact factor: 7.038

5.  Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival.

Authors:  Cristina R Ferrone; Michael W Kattan; James S Tomlinson; Sarah P Thayer; Murray F Brennan; Andrew L Warshaw
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

6.  Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.

Authors:  Adam C Berger; Ingrid M Meszoely; Eric A Ross; James C Watson; John P Hoffman
Journal:  Ann Surg Oncol       Date:  2004-06-14       Impact factor: 5.344

7.  Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients.

Authors:  Jonathan E Lim; Michael W Chien; Craig C Earle
Journal:  Ann Surg       Date:  2003-01       Impact factor: 12.969

8.  Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005).

Authors:  Michele M Corsini; Robert C Miller; Michael G Haddock; John H Donohue; Michael B Farnell; David M Nagorney; Aminah Jatoi; Robert R McWilliams; George P Kim; Sumita Bhatia; Matthew J Iott; Leonard L Gunderson
Journal:  J Clin Oncol       Date:  2008-07-20       Impact factor: 44.544

9.  Benefit of postoperative adjuvant therapy for pancreatic cancer: A population-based analysis.

Authors:  Kimberly A Vanderveen; Steven L Chen; Daixin Yin; Rosemary D Cress; Richard J Bold
Journal:  Cancer       Date:  2009-06-01       Impact factor: 6.860

10.  Ductal adenocarcinoma of the pancreas: clinicopathologic features and survival.

Authors:  C Sperti; B Bonadimani; C Pasquali; A Piccoli; F Cappellazzo; M Rugge; S Pedrazzoli
Journal:  Tumori       Date:  1993-10-31
View more
  16 in total

Review 1.  Indications for staging laparoscopy in pancreatic cancer.

Authors:  Antonella De Rosa; Iain C Cameron; Dhanwant Gomez
Journal:  HPB (Oxford)       Date:  2015-11-18       Impact factor: 3.647

2.  Neoadjuvant therapy prior to surgical resection for previously explored pancreatic cancer patients is associated with improved survival.

Authors:  Fengchun Lu; Kevin C Soares; Jin He; Ammar A Javed; John L Cameron; Neda Rezaee; Timothy M Pawlik; Christopher L Wolfgang; Matthew J Weiss
Journal:  Hepatobiliary Surg Nutr       Date:  2017-06       Impact factor: 7.293

3.  Elevated STMN1 Expression Correlates with Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma.

Authors:  Jian Li; Guohuang Hu; Fujiao Kong; Kemin Wu; Kun Song; Jianfeng He; Weijia Sun
Journal:  Pathol Oncol Res       Date:  2015-03-20       Impact factor: 3.201

4.  Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in BRCA1 and BRCA2.

Authors:  Amethyst Saldia; Sara H Olson; Pamela Nunes; Xiaolin Liang; Marguerite L Samson; Erin Salo-Mullen; Vanessa Marcell; Zsofia K Stadler; Peter J Allen; Kenneth Offit; Robert C Kurtz
Journal:  Cancer Prev Res (Phila)       Date:  2019-07-23

5.  Extended lymphadenectomy benefits patients with borderline resectable pancreatic head cancer-a single-center retrospective study.

Authors:  Jing Wang; Shao-Cheng Lyu; Ji-Qiao Zhu; Xian-Liang Li; Ren Lang; Qiang He
Journal:  Gland Surg       Date:  2021-10

6.  Is tumour size an underestimated feature in the current TNM system for malignancies of the pancreatic head?

Authors:  David Petermann; Nicolas Demartines; Markus Schäfer
Journal:  HPB (Oxford)       Date:  2013-01-29       Impact factor: 3.647

7.  Young patients undergoing resection of pancreatic cancer fare better than their older counterparts.

Authors:  Jin He; Barish H Edil; John L Cameron; Richard D Schulick; Ralph H Hruban; Joseph M Herman; Lei Zheng; Christine Iacobuzio-Donahue; Nita Ahuja; Timothy M Pawlik; Christopher L Wolfgang
Journal:  J Gastrointest Surg       Date:  2012-11-27       Impact factor: 3.452

8.  Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: ≤2, pT2: >2-≤4, pT3: >4 cm) is More Valid and Clinically Relevant.

Authors:  Burcu Saka; Serdar Balci; Olca Basturk; Pelin Bagci; Lauren M Postlewait; Shishir Maithel; Jessica Knight; Bassel El-Rayes; David Kooby; Juan Sarmiento; Takashi Muraki; Irma Oliva; Sudeshna Bandyopadhyay; Gizem Akkas; Michael Goodman; Michelle D Reid; Alyssa Krasinskas; Rhonda Everett; Volkan Adsay
Journal:  Ann Surg Oncol       Date:  2016-01-29       Impact factor: 5.344

9.  Prognostic value of gross tumor volume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy.

Authors:  Cem Parlak; Erkan Topkan; Cem Onal; Mehmet Reyhan; Ugur Selek
Journal:  Radiat Oncol       Date:  2012-03-19       Impact factor: 3.481

10.  Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages.

Authors:  Jun Yu; Amanda L Blackford; Marco Dal Molin; Christopher L Wolfgang; Michael Goggins
Journal:  Gut       Date:  2015-01-30       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.